6/25/2025

Source: SeekingAlpha

6/24/2025

SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use/CHMP adopted a positive opinion recommending the approval of nirogacestat. The oral gamma secretase inhibitor is proposed as a monotherapy for adults with […]

Source: Yahoo

6/20/2025

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., June 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Hu

Source: Yahoo

6/3/2025

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of SpringWorks Therapeutics, Inc. to Merck KGaA,...

Source: Finnhub

5/28/2025

Small-cap stocks experienced a broad drawdown in Q1 with the Russell 2000® Growth Index (down 11.12%) trailing the Russell 2000® Value Index (down 7.74%) by a notable margin.

Source: SeekingAlpha

5/27/2025

The U.S. stock market has experienced significant volatility recently, with major indices like the Dow Jones and Nasdaq Composite seeing sharp gains following a tech sector rally driven by shifts in trade policy under the Trump administration. In this dynamic environment, high-growth tech stocks can be particularly appealing to investors seeking opportunities that align with current market momentum and technological advancements.

Source: Yahoo

5/23/2025

– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., May 23, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the European Medicines Agency’s (EMA) Committee fo

Source: Yahoo

5/9/2025

STAMFORD, Conn. — STAMFORD, Conn. — SpringWorks Therapeutics Inc. on Friday reported a loss of $83.2 million in its first quarter. The Stamford, Connecticut-based company said it had a loss...

Source: Finnhub

5/9/2025

Biotech ETFs face sharp declines, but strong operational momentum in select companies offers investment opportunities.

Source: SeekingAlpha

5/1/2025

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr

Source: Yahoo

5/1/2025

NEW YORK, May 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

Source: Finnhub

4/29/2025

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on SWTX and MKGAF stock post deal.

Source: SeekingAlpha

4/28/2025

NEW YORK, April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. and its board of directors concerning the proposed...

Source: Finnhub

4/28/2025

Online retailer Temu — owned by PDD Holdings (PDD) — aims to raise prices amid tariffs, while Tesla (TSLA) raises its EV prices in Canada and Merck KGaA (MRK) seeks to acquire SpringWorks Therapeutics (SWTX) in a $3.9 billion deal. Catalysts host Madison Mills and Ritholtz Wealth Management chief market strategist Callie Cox weigh in on these top stocks. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

Source: Yahoo

4/28/2025

Germany’s Merck agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business.

Source: Yahoo

4/28/2025

The Ademi Firm is investigating SpringWorks for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.Click here to learn how to join our investigation and...

Source: Finnhub

4/28/2025

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of SpringWorks Therapeutics, Inc. to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash is fair to...

Source: Finnhub

4/28/2025

Huawei preparing to test latest AI chip to challenge Nvidia (NVDA): report. Merck KGaA to buy Springworks for $3.9 billion. CrowdStrike unveils new AI agents for cybersecurity.

Source: SeekingAlpha

4/28/2025

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for

Source: Yahoo

4/27/2025

STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumor

Source: Yahoo